Palisade Bio Says FDA Clears IND Application For PALI-2108, Enabling Initiation Of Global Phase 2 ASCENTRA-UC Clinical Trial In Patients Wit
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027 IND clearance marks a major development milestone for PALI